9 Stocks on Jim Cramer’s Radar

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 62

Cramer discussed how Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) keeps getting undermined despite the company’s rich pipeline and its strength in drug development.

“How about Regeneron? Now, here’s a stock that traded at $1,211 in August of last year. Now, after declining nearly 4% today alone, it sits at $690. Wow. The issue, Regeneron has this fabulous eyecare franchise being challenged by an Amgen biosimilar. By the way, that’s a biotech version of just a generic drug but that’s all Wall Street cares about.

Doesn’t matter that Regeneron is working on 40 different compounds, many of which could be blockbusters, doesn’t matter if their breakthrough drug Dupixent is indicated for seven gigantic illnesses, asthma, eczema, [and] nasal polyps. This company has never lost its ability to develop new medicines, including the one that likely saved President-Elect Trump’s life when he caught Covid near the end of his first term. For now, none of that seems to matter, but you know, one day it will.”

Regeneron (NASDAQ:REGN) creates and brings to market medications for various health conditions, while also concentrating on the development of innovative therapies for multiple medical issues. Bronte Capital stated the following regarding Regeneron (NASDAQ:REGN) in its Q3 2024 investor letter:

“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – the biggest loser in the book by absolute dollars. Regeneron is a large position for us. We wrote the position up in June 2021 letter. The stock has almost doubled since the original write-up, but it is down on the month. Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way.

Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.

Eylea is a VEGF drug that is injected into patients’ eyes and stops macular degeneration (the main cause of blindness in old people). The drug stops capillaries growing in the retina…” (Click here to read the full text)